- Home
- CFB vs COGT Comparison
CFB vs COGT Comparison
Compare CFB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFB
- COGT
- Stock Information
- Founded
- CFB 2007
- COGT 2014
- Country
- CFB United States
- COGT United States
- Employees
- CFB N/A
- COGT N/A
- Industry
- CFB Major Banks
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CFB Finance
- COGT Health Care
- Exchange
- CFB Nasdaq
- COGT Nasdaq
- Market Cap
- CFB 854.1M
- COGT 900.3M
- IPO Year
- CFB 2019
- COGT 2018
- Fundamental
- Price
- CFB $16.72
- COGT $7.82
- Analyst Decision
- CFB Strong Buy
- COGT Buy
- Analyst Count
- CFB 5
- COGT 6
- Target Price
- CFB $18.80
- COGT $14.20
- AVG Volume (30 Days)
- CFB 175.3K
- COGT 1.7M
- Earning Date
- CFB 01-21-2025
- COGT 11-12-2024
- Dividend Yield
- CFB N/A
- COGT N/A
- EPS Growth
- CFB 19.65
- COGT N/A
- EPS
- CFB 1.47
- COGT N/A
- Revenue
- CFB $242,671,000.00
- COGT N/A
- Revenue This Year
- CFB N/A
- COGT N/A
- Revenue Next Year
- CFB $9.11
- COGT N/A
- P/E Ratio
- CFB $11.31
- COGT N/A
- Revenue Growth
- CFB 7.66
- COGT N/A
- 52 Week Low
- CFB $10.64
- COGT $4.28
- 52 Week High
- CFB $19.22
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CFB 42.85
- COGT 32.81
- Support Level
- CFB $16.54
- COGT $7.94
- Resistance Level
- CFB $17.14
- COGT $8.56
- Average True Range (ATR)
- CFB 0.36
- COGT 0.60
- MACD
- CFB -0.12
- COGT -0.06
- Stochastic Oscillator
- CFB 14.75
- COGT 9.60
About CFB CrossFirst Bankshares Inc.
CrossFirst Bankshares Inc is engaged in providing banking and financial services to businesses, business owners, professionals, and professional networks. The services offered by the company includes Checking accounts, Savings accounts, Personal Loans, International Banking, Business Loans, and Treasury services. The company generates revenue from interest income and fees on loans and interest earned from its marketable securities portfolio.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.